PEACH Life Science, a Korean startup developing electronic medicine based on materials, parts, and equipment (MPE) technology, has secured seed funding from a fund jointly managed by Yonsei Biohealth Technology Holdings and InnoCube.

PEACH Life Science is one of the few domestic startups specializing in electronic medicine with proprietary circuit and electrode technologies grounded in MPE. While the global electronic medicine market largely depends on similar diagnostic and therapeutic protocols, the company differentiates itself through enhanced safety in electrode and circuit design, along with a user-friendly system architecture.

The company has further demonstrated its business viability and growth potential by consecutively advancing through major national startup support programs, including TIPA(Technology Information Promotion Agency for SME) Value Up, Kibo Venture Camp(program operated by the Korea Technology Finance Corporation (Kibo)), and the Korea Credit Guarantee Fund’s Newborn Penguin initiative. Currently, it is conducting joint research and clinical trials in collaboration with Severance Hospital to achieve technological and medical validation.

CEO Jaejun Park stated, “This investment represents a dual validation from both academia and industry. Going forward, we aim to introduce our bioelectronic solutions across the U.S., Europe, and Asia, presenting a global expansion model for Korea’s MPE-based neuroengineering startups.”

Meanwhile, Yonsei Biohealth Technology Holdings was established to identify and commercialize advanced technologies in the bio-medical sector through academia-industry collaboration. InnoCube, a subsidiary of Handok and a bio-healthcare accelerator, supports promising startups with early-stage funding, as well as access to shared research spaces and laboratory infrastructure.